We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First Mobile Diagnostic System Performs Instant Lab Quality Blood Analysis Anywhere

By LabMedica International staff writers
Posted on 25 Aug 2023

Presently, the complete blood count (CBC) is one of the most frequently recommended diagnostic tests to evaluate an individual's overall health by measuring factors like oxygen-transporting red blood cells, infection-combating white blood cells, and blood-coagulating platelets. More...

However, there are issues with CBC testing such as patient expenses, accessibility, and time consumption. Patients require a referral, followed by scheduling a nurse appointment for blood collection. This is followed by waiting in the clinic, and sometimes waiting for hours or days after the blood draw to obtain the results. Moreover, a substantial portion of the global population lacks access to proper diagnostics due to distance from clinics or financial constraints. Now, a groundbreaking diagnostic system is making waves in the point of care (POC) setting, offering the first mobile technology for instant blood analysis beyond the confines of a lab. This innovation has the potential to bring lab tests within reach of millions worldwide.

The REVDX from EFA Technologies (Caesarea, Israel) is a portable lab-quality device that incorporates advanced multi-channel technology. This handheld device can be used anywhere, eliminating the need for time-consuming preparations or specialized knowledge. It is mobile, portable, and handheld, capable of functioning without electricity or internet connectivity, while also being cost-effective. At present, the device can conduct a blood count, with plans for additional tests in the future. A simple finger prick is all that's required, eliminating the need to visit a lab and delivering results in just minutes. The device aims to empower doctors and medical teams in diverse scenarios to make informed treatment decisions promptly, bypassing the wait time for blood tests and their subsequent results. The REVDX is user-friendly, operating via a finger prick and independent of elaborate lab conditions or specific preparations.

In patients with fever, the most critical test to conduct is a CBC. These results can assist in administering antibiotics for suspected bacterial infections, avoiding unwarranted antibiotic use in viral infections, and identifying parasitic infections like malaria. Presently, most labs provide CBC results within 24 to 72 hours, with a significant time lapse during test transportation. The absence of real-time blood count data contributes to antibiotic overuse, which exacerbates antimicrobial resistance (AMR). REVDX has the capability to conduct automated microscopy tests, encompassing full blood sampling and immediate full blood count diagnosis. Physicians can utilize REVDX to make real-time, informed judgments about the likelihood of a bacterial infection, curtailing unnecessary antibiotic use. This positions REVDX as an indispensable device for every point of need across the world.

Related Links:
EFA Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.